Table 2.
Characteristics of included trials in the first meta-analysis.
| Diagnosis | Medication (MED) | Chrono-therapy (CT) | Mean age (range or SD), years |
Primary outcome instrument |
Duration of treatment | MED | TSD+MED | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | D | AS | n | D | AS | |||||||
| Benedetti et al. (25) Nondouble-blind. Randomized controlled trial. |
Bipolar depression (DSM-III-R) | Fluoxetine | TSD (3 cycles) | 40 ± 12.1, 42 ± 9.7 |
HDRS-17 | 1 month | 5 | 0 | NR | 5 | 0 | NR |
| Wu et al. (11) Nondouble-blind. Randomized controlled trial. |
Bipolar disorder, Major depressive episode (DSM-IV) | Lithium or other mood stabilizer, sertraline or other antidepressant |
TSD (1 cycles), Bright light therapy, SPA (3 cycles) | 39 ± 13.3, 40 ± 14.1 |
HDRS-19 | 7 weeks | 17 | 0 | 0 | 32 | 5 | 2 |
MED, Medication; CT, Chronotherapy; SD, Standard deviation; DSM, Diagnostic and Statistical Manual; TSD, Total sleep deprivation; HDRS, Hamilton depression rating scale; SPA, Sleep phase advance; n, Sample size; D, Dropout; AS, Affective Switch.